Biocon Secures USFDA Nod for gSaxenda in Weight Management

announced on February 24, 2026, that it received USFDA approval for its Liraglutide Injection gSaxenda, a 18 mg/3 mL (6 mg/mL) prefilled pen formulation. This drug-device combo serves as an adjunct to diet and exercise for chronic weight management, tapping into the fast-expanding GLP-1 receptor agonist class amid rising obesity rates.​ The US market for GLP-1 therapies in weight loss stood at $127 million per IQVIA MAT December 2025 data, underscoring significant commercial potential. Biocon's CEO Siddharth Mittal emphasized the approval as validation of the firm's integrated platform, with plans for swift US commercialization to offer affordable access. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.